Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington's Disease

Skyhawk Therapeutics Denmark Finland France Germany Netherlands Sweden United Kingdom Massachusetts

View original content:https://www.prnewswire.co.uk/news-releases/skyhawk-therapeutics-receives-hrec-approval-for-a-phase-1-study-of-its-sky-0515-rna-targeting-small-molecule-for-huntingtons-disease-301964052.html